Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety Study of Entinostat
NCT02897778Phase 1Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in solid tumor comparing Entinostat with Placebo (2 arms). Primary endpoints: Change from Baseline in Heart Rate, Change from Baseline in Electrocardiogram Procedures and 1 more. Started Aug 2016; status: completed.
02
Drugs
entinostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02897778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897778.